01:06 PM EDT, 06/20/2024 (MT Newswires) -- (Updates to add stock move in the headline and the first paragraph.)

ImmunityBio ( IBRX ) shares rose more than 8% in recent trading Thursday after the company said it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio ( IBRX ).

Price: 6.75, Change: +0.52, Percent Change: +8.27